BCR-ABL阴性的骨髓增殖性肿瘤中PD-1和PD-L1的表达研究  

Expression of PD1 and PD-L1 in BCR-ABL negative myeloproliferative tumors

作　　者：彭芳[1] 钟斌[2,3] 张功亮 王建[1] 王志[1] PENG Fang;ZHONG Bin;ZHANG Gong-liang;WANG Jian;WANG Zhi(Department of Pathology,Ganzhou People's Hospital;Department of Pharmacy,The First Affiliated Hospital of Gannan Medical University;Ganzhou Key Laboratory of Immunotherapeutic Drugs Developing for Childhood Leukemia,Ganzhou,Jiangxi 341000)

机构地区：[1]赣州市人民医院病理科 [2]赣南医学院第一附属医院药学部 [3]赣州市儿童白血病肿瘤免疫治疗药物研发重点实验室,江西赣州341000

出　　处：《赣南医学院学报》2022年第6期587-590,共4页JOURNAL OF GANNAN MEDICAL UNIVERSITY

基　　金：赣州市指导性科技计划项目(GZ2019ZSF091);赣州市卫生健康委员会市级科研计划项目(2019-2-1)。

摘　　要：目的:探讨BCR-ABL阴性的骨髓增殖性肿瘤中程序性死亡受体1(programmed death 1,PD-1)及其配体PD-L1的表达。方法:分析30例BCR-ABL阴性的骨髓增殖性肿瘤的临床资料、病理形态学特征及PD-1和PD-L1免疫组化表达情况,并结合相关文献进行复习。结果:PD-1阳性率:真性红细胞增多症阳性率20.0%,原发性血小板增多症阳性率30.0%,原发性骨髓纤维化阳性率20.0%,总阳性率23.3%;PD-L1阳性率:真性红细胞增多症阳性率20.0%,原发性血小板增多症阳性率30.0%,原发性骨髓纤维化阳性率33.3%,总阳性率30.0%。结论:BCR-ABL阴性的骨髓增殖性肿瘤患者通常存在PD-1和PD-L1过度表达,其表达阳性率和表达水平均高于骨髓活检大致正常的患者。Objective:To explore the expression of programmed death 1(PD-1)and programmed death-ligand 1(PD-L1)in BCR-ABL negative myeloproliferative diseases.Methods:The clinical data,pathomorphological features,immunohistochemical expression of PD-1 and PD-L1 of 30 cases with bcr-abl negative myeloproliferative tumors were analyzed,combined with relevant literature review.Results:The positive rates of PD-1:The positive rates of polycythemia vera,thrombocytosis and myelofibrosis were 20.0%,30.0% and 20.0%,respectively,and the total positive rates was23.3%.The positive rates of PD-L1:The positive rates of polycythemia vera,thrombocytosis and myelofibrosis were20.0%,30.0% and 33.3% respectively,and the total positive rates was 30.0%.Conclusion:Patients with BCR-ABL negative myeloproliferative tumors usually have overexpression of PD-1 and PD-L1,and their positive rate and expression level are higher than those with normal bone marrow biopsy.

关 键 词：骨髓增生性疾病 程序性死亡受体1 细胞程序性死亡配体1 

分 类 号：R730.2[医药卫生—肿瘤]